A Study to Evaluate ONM100, an Intraoperative Fluor Imaging Agent for the Detection of Peri Mets
A Phase 2, Open-Label Study to Evaluate the Performance and Safety of ONM100, an Intraoperative Fluor Imaging Agent for the Detection of Peritoneal Mets
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Trials@OncoNanoMed.com
- Phone Number: (682) 285-1411
- Email: trials@onconanomed.com
Study Locations
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest Baptist Health
-
-
Ohio
-
Columbus, Ohio, United States, 43201
- The Ohio State University Wexner Medical Center / James Cancer Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19146
- Perelman School of Medicine, University of Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15212
- AHN Cancer Institute, West Penn Hospital
-
-
Texas
-
Houston, Texas, United States, 77030
- The University of Texas MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Imaging and biopsy confirmed metastatic disease of peritoneal origin
Exclusion Criteria:
- Known hypersensitivity or allergy to any component of pegsitacianine
- Tumor locations the surgeon deems unfeasible to image intraoperatively
- Excessive and/or generalized metastatic disease deemed inoperative by the surgeon
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Fluorescence imaging with pegsitacianine
1 mg/kg of pegsitacianine administered IV 24-72 hours prior to surgery.
|
An intraoperative nanoparticle-based fluorescence imaging agent comprised of micelles covalently conjugated to indocyanine green (ICG).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Patients That Had at Least One Additional Lesion Detected Under Pegsitacianine Guidance Following CRS That Was Confirmed as Positive for Disease by Pathological Evaluation
Time Frame: 1 day
|
Percentage of patients that had at least one additional lesion detected under pegsitacianine guidance following standard of care cytoreductive surgery that would have been left behind had imaging not been performed and was confirmed to be positive for disease by pathological evaluation.
|
1 day
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sensitivity of Pegsitacianine at Detecting Presence of Tumor Within the Tissue Specimen
Time Frame: 7 days
|
# of true positive specimens divided by the (#of true positive specimens + # of false negative specimens)
|
7 days
|
|
Specificity of Pegsitacianine at Detecting Presence of Tumor Within the Tissue Specimen
Time Frame: 7 days
|
# of True Negative Specimens divided by the (# of True Negative Specimens + # of False Positive Specimens)
|
7 days
|
|
Negative Predictive Value of Pegsitacianine
Time Frame: 7 days
|
# of True negative specimens divided by the (# of true negative specimens + # of false negative specimens)
|
7 days
|
|
Positive Predictive Value of Pegsitacianine
Time Frame: 7 days
|
# of true positive specimens divided by the (# of true positive + # of false positive specimens)
|
7 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Patrick Wagner, MD, Allegheny Health Network
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ON-1003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.